What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: TechSci Research | PRODUCT CODE: 1117685

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1117685

United Kingdom Monkeypox Therapeutics Market, By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin ), By End User, By Region, Competition Forecast & Opportunities, 2027

PAGES: 72 Pages
DELIVERY TIME: 2-3 business days
Unprintable PDF (Single User License)
USD 3500
PDF and Excel (Multi-User License)
USD 4500
PDF and Excel (Custom Research License)
USD 7500

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

The United Kingdom monkeypox therapeutics market is projected to register growth at a formidable rate during the forecast period, 2023-2027. The market growth can be attributed to the rising incidences of monkeypox in the country and expanding population with weak immunity.

Monkeypox is a virus with a rapid pace of dissemination. According to the World Health Organization, the illness has a 3-6% death rate and causes fever, excruciating headaches, swollen lymph nodes, and other symptoms (WHO). Through close contact with respiratory secretions and skin lesions, the disease can be transferred from one person to another. Generally, prolonged face-to-face contact is necessary for the transmission of respiratory droplet particles, putting health workers, household members, and other close contacts of active cases at risk.

The rapid spread of monkeypox is boosting the market's growth by driving the demand for emergency medications for timely and efficient treatment. Additionally, researchers around the United Kingdom are constantly working to create pharmaceuticals in large quantities so that more patients can avail them. To enable the development of new drugs to stop the spread of monkeypox around the world, research and development operations need to make significant expenditures on cutting-edge machinery and technologies.

Some of the primary growth-inducing elements for the monkeypox treatments market are the expanding infrastructure and the simple accessibility to healthcare facilities. The United Kingdom provides its residents with modern, state-of-the-art healthcare facilities that raise awareness of a variety of disorders. Additionally, the necessity to get tested if experiencing any symptoms is driven by the public's growing knowledge of the monkeypox virus. This increases the need for hospitals or clinics to provide quality medical care.

The United Kingdom monkeypox therapeutics market is segmented on the basis of treatment, end user, regional distribution, and competitive landscape. Based on end user, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is anticipated to dominate the United Kingdom monkeypox therapeutics market, owing to the increasing number of patients getting admitted to the hospital to seek treatment for the virus rather than in other healthcare systems.

Major players operating in the United Kingdom monkey therapeutics market are Chimerix UK Limited, SIGA Technologies, Inc., Emergent BioSolutions UK Ltd., Bavarian Nordic A/S, Mylan N.V., Olon S.p.A., Teva UK Limited, among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

  • To analyze the historical growth in the market size of the United Kingdom monkeypox therapeutics from 2017 to 2021.
  • To estimate and forecast the market size of United Kingdom monkeypox therapeutics market from 2023 to 2027 and growth rate until 2027.
  • To classify and forecast the United Kingdom monkeypox therapeutics market based on treatment, end user, region, and company.
  • To identify the dominant region or segment in the United Kingdom monkeypox therapeutics market.
  • To identify drivers and challenges for the United Kingdom monkeypox therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the United Kingdom monkeypox therapeutics market.
  • To identify and analyze the profiles of leading players operating in the United Kingdom monkeypox therapeutics market.
  • To identify key sustainable strategies adopted by market players in United Kingdom monkeypox therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the service providers and presence of all major players across the country.

TechSci Research calculated the market size of the United Kingdom monkeypox therapeutics market using a top-down approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums, and alliances

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as service providers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, United Kingdom monkeypox therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • United Kingdom Monkeypox Therapeutics Market, By Treatment:

Smallpox Vaccine


Vaccinia Immune Globulin (VIG)

  • United Kingdom Monkeypox Therapeutics Market, By End User:


Specialty Clinics

Ambulatory Surgical Centers


  • United Kingdom Monkeypox Therapeutics Market, By Region:



East Anglia



East Midlands

Yorkshire & Humberside

Rest of United Kingdom

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United Kingdom monkeypox therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Product Code: 11720

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on United Kingdom Monkeypox Therapeutics Market

4. Executive Summary

5. Voice of Customer

6. United Kingdom Monkeypox Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
    • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Region
    • 6.2.4. By Company (2021)
  • 6.3. Product Market Map

7. London Monkeypox Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User

8. East Anglia Monkeypox Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User

9. Southwest Monkeypox Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User

10. Southeast Monkeypox Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User

11. Scotland Monkeypox Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Treatment
    • 11.2.2. By End User

12. East Midlands Monkeypox Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Treatment
    • 12.2.2. By End User

13. Yorkshire & Humberside Monkeypox Therapeutics Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Treatment
    • 13.2.2. By End User

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Policy & Regulatory Landscape

17. Import-Export Analysis

18. United Kingdom Economic Profile

19. Competitive Landscape

  • 19.1. Chimerix UK Limited
  • 19.2. SIGA Technologies, Inc.
  • 19.3. Emergent BioSolutions UK Ltd.
  • 19.4. Bavarian Nordic A/S
  • 19.5. Mylan N.V.
  • 19.6. Olon S.p.A.
  • 19.7. Teva UK Limited

20. Strategic Recommendations

Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!